Skip to main content
. 2019 Jul 22;11(7):1028. doi: 10.3390/cancers11071028

Table 1.

Enrichment of BCSC following endocrine treatment.

Treatment System 1 BCSC 2 Ref.
Tamoxifen MCF7-TamR CD44+CD24−/low [70]
Tamoxifen MCF7-TamR CD44+CD24−/low
Mammosphere		 [71]
Tamoxifen MCF7-TamR ALDH1+ [72]
Tamoxifen MCF7-TamR CD133+
Mammosphere		 [73]
Tamoxifen MCF7 and LM05-E, 5 days treatment Mammosphere [74]
Tamoxifen MCF7-TamR CD44+CD24−/low [74]
Tamoxifen LM05-E xenografts 3 CD29hiCD24low [74]
Letrozole Patient BCs CD44+CD24−/low [75]
Tamoxifen 4
Fulvestrant 4 		Patient-derived mammosphere, 7–9 days
Patient-derived xenograft, 14 days		 ALDH1+ [76]

1 systems and conditions used to derive endocrine resistance; 2 BCSC populations; 3 murine tumor; 4 both cells isolated from patients samples or patient-derived xenografts were treated individually with tamoxifen and fulvestrant.